Lv1
38 积分 2024-06-21 加入
Anti-Drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route
13天前
已完结
Claudin 18.2 as a novel therapeutic target
16天前
已完结
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer
17天前
已完结
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
21天前
已完结
Who wins the combat, CAR or TCR?
28天前
已完结
Bispecific antibody takes a BiTE out of B cells in rheumatoid arthritis
1个月前
已完结
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
1个月前
已完结
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past
1个月前
已完结
Novel strategies in the treatment of acute lymphoblastic leukaemia
1个月前
已完结
Bispecific antibodies
1个月前
已完结
皖公网安备34019202002308
